Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Rinuagene International Hk Limited has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is handled by 1 distinct examiner, KELLY, ROBERT M. The prosecution involves 1 distinct art unit, which indicates a highly focused technical scope for the company's biological research. KELLY, ROBERT M is the busiest examiner, currently managing 1 pending action. This distribution reflects a prosecution strategy that is concentrated within a single specialized group at the USPTO. The presence of 1 distinct art unit suggests that the company's patent application is being reviewed by a single specialized technical group.
With 1 distinct examiner, the company's patent prospects are entirely dependent on the individual evaluation of KELLY, ROBERT M. This 1 pending office action represents the totality of the company's current pending workload. KELLY, ROBERT M, who is the busiest examiner with 1 pending action, handles the only pending matter for the company. This focused prosecution landscape requires a legal strategy tailored to the specific standards of 1 distinct art unit. The fact that 1 distinct examiner is involved in 1 pending office action ensures a direct and streamlined interaction with the USPTO. For a patent practitioner, this concentration allows for a highly specific approach to the 1 pending office action currently under review.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KELLY, ROBERT M | 1 | 74.1% | +24.1% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19408745 | EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE | KELLY, ROBERT M | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19408745 | EXPRESSION-ADJUSTABLE ENGINEERED RNA MOLECULE | KELLY, ROBERT M | 1638 | §112 | Non-Final OA | — | Pending | Dec 04, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialRinuagene International Hk Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Robert M Kelly has the most, with 1 of Rinuagene International Hk Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
